A total of 1132 clinical isolates from 952 patients with nosocomial infections were tested against the fluoroquinolone trovafloxacin by the agar dilution method. They comprised 285 staphylococci, 111 streptococci, 94 enterococci and 470 isolates of Enterobacteriaceae, 92 Pseudomonas aeruginosa, 27 Stenotrophomonas maltophilia, 28 Haemophilus influenzae and 25 Acinetobacter calcoaceticus. The in-vitro activity of trovafloxacin was compared with that of ciprofloxacin, norfloxacin, -lactam and aminoglycoside agents. Over 96% of Enterobacteriaceae were susceptible to trovafloxacin with an MIC of ≤0.03-4 mg/L. It also inhibited 97% and 100% clinical isolates of P. aeruginosa and S. maltophilia, respectively. All staphylococci, including 51 strains of methicillin-resistant Staphylococcus aureus, were susceptible to trovafloxacin, which also had excellent activity against streptococci and enterococci, inhibiting all 111 strains of the former and 94% of the latter. Trovafloxacin had a greater activity against both Gram-positive and Gram-negative bacteria than ciprofloxacin, norfloxacin, penicillins, cephalosporins and the aminoglycosides tested.
Introduction
A number of fluoroquinolones, developed from modification of the nalidixic acid molecule, have emerged as potentially useful antimicrobial agents. [1] [2] [3] [4] [5] Since modifications of the parent compound could result in a broader spectrum of antimicrobial activity, better penetration and improved pharmacokinetic properties, the search continues for more potent drugs: trovafloxacin (CP-99,219) is one such drug in the initial stages of development. In this paper we present a study of the antibacterial activity of trovafloxacin against clinical isolates from patients with nosocomial infections and compare its activity with that of other commonly used antimicrobial agents.
Materials and methods

Bacterial strains
The bacteria were recent clinical isolates cultured during the period 1st April 1995 to 30th September, 1995, from patients at the King Faisal Specialist Hospital & Research Centre, a 550-bed tertiary care facility in Riyadh, Saudi Arabia. All isolates studied were nosocomial, i.e. the patients did not have an infection when admitted to hospital, and developed it at least 3 days after admission. Only one bacterial strain from each patient was used to avoid testing of duplicate isolates. The organisms were identified by standard methods. 6 All strains were stored at 4°C in trypticase soy broth, obtained from BBL (Cockeysville, MD, USA), until use.
Susceptibility testing
Antimicrobial susceptibilities of the isolates were determined by an agar dilution method, according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS). 7 The results were recorded as MICs. The MIC 50 and MIC 90 were defined as the minimum concentration of antimicrobial that inhibited 50% or 90% of the isolates, respectively. Mueller-Hinton agar with or without 5% sheep blood (Difco Laboratories, Detroit, MI, USA), with a pH range of 7.2-7. 4 a Although the susceptibility breakpoint for trovafloxacin has not been established, based on experience with other fluoroquinolones, 2,4,6,7 we considered bacteria resistant when the MIC for this drug exceeded 4 mg/L. described 7 and inoculated with a Steers replicator (Craft Machines, Inc., Chester, PA, USA). All organisms were incubated at 35°C for 18-24 h in the ambient air or CO 2 incubator, depending upon bacterial isolate. Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 29213 were used as control organisms. The control results were within expected ranges during this investigation. Although the susceptibility breakpoint for trovafloxacin has not been established, based on experience of other fluoroquinolones, 2, 4, 6, 7 the bacteria were deemed resistant when the MIC of this drug exceeded 4 mg/L. Other antimicrobial agents were purchased from commercial sources. The drugs were stored, dissolved and diluted as recommended by the manufacturers or the NCCLS. 
Results
In this prospective study, we analysed the data from 952 patients with hospital-acquired infections. A total of 1132 nosocomial pathogens were isolated. The bacterial isolates comprised 124 strains of methicillin-sensitive and 51 strains of methicillin-resistant S. aureus, 110 coagulase-negative staphylococci, 94 enterococci, 111 streptococci, 470 strains of Enterobacteriaceae and 172 other Gram-negative bacilli. The commonest source of nosocomial isolates was urine (31%), followed by blood (28%), respiratory tract (16%), skin, soft tissue and wound (12%) and other miscellaneous sources (13%). The MIC 50 s and MIC 90 s for the tested bacterial species are presented in the Table. Trovafloxacin had good inhibitory activity against Enterobacteriaceae. Ninety-seven per cent of the 92 isolates of P. aeruginosa were inhibited by 4 mg/L of this quinolone. Similarly, all isolates of Stenotrophomonas maltophilia, a species notoriously resistant to antimicrobial agents, were susceptible to trovafloxacin at concentrations of 0.03-2 mg/L. All the 285 isolates of staphylococci, including 51 methicillin-resistant S. aureus and the 111 strains of streptococci were susceptible to trovafloxacin. Of the drugs tested, trovafloxacin had the broadest spectrum of activity against the bacterial species studied.
Discussion
Data from the Center for Disease Control & Prevention showed that 5-6% of hospitalized patients in the USA develop nosocomial infections, the rate being higher in large tertiary-care, referral and teaching hospitals. 8 It is estimated that nosocomial infections prolong hospitalization by an average of 3.5 days, with an annual cost of more than US$2 billion in the USA alone. In 1981, a survey of 18,163 patients in 43 hospitals in the UK showed that 9.3% of the infections were hospital-acquired. 9 Nosocomial infections in the UK are believed to result in an additional burden of 950,000 bed days at a hospital cost of more than US$115 million (not counting indirect costs, such as lost productivity). 9 Bacteria are, by far, the most important cause of nosocomial infections. Since bacterial isolates from nosocomial infections in developing countries have a higher frequency of resistance than those isolated in the Western hemisphere, [10] [11] [12] [13] [14] we tested the in-vitro activity of the new fluoroquinolone trovafloxacin against 1132 such pathogens isolated from 952 patients. We found trovafloxacin to have a broad-spectrum of antibacterial activity; the organisms it was active against included some that were resistant to aminoglycosides, broad-spectrum cephalosporins and methicillin. The overall spectrum of activity of trovafloxacin was better than or comparable to that of ciprofloxacin and norfloxacin. Our findings are consistent with those reported elsewhere, 1,15-18 even though our isolates were markedly more resistant to other, commonly used, antimicrobial agents. With its good activity against a wide variety of Gram-positive and Gramnegative bacteria of medical importance, trovafloxacin appears to be a suitable treatment for nosocomial infections.
Most quinolones are highly active against aerobic Gramnegative bacilli, but many have only modest activity against Gram-positive organisms. Trovafloxacin is a particularly promising quinolone because of its high degree of activity against both Gram-positive and Gram-negative organisms.
